Global Information
회사소개 | 문의 | 위시리스트

외상후 스트레스 장애(PTSD) : 파이프라인 리뷰

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2019

리서치사 Global Markets Direct
발행일 2019년 02월 상품 코드 213134
페이지 정보 영문 142 Pages
가격
US $ 2,000 ₩ 2,429,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,858,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,287,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


외상후 스트레스 장애(PTSD) : 파이프라인 리뷰 Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2019
발행일 : 2019년 02월 페이지 정보 : 영문 142 Pages

외상후 스트레스 장애(PTSD)는 경험했거나 목격한 무서운 사건에 의해 발생하는 정신 위생 상태입니다. 증상에는 플래시백, 악몽 및 중증 불안 뿐만 아니라 그 사건에 관해 제어하지 못하는 사고가 포함됩니다. 치료에는 항우울제, 항불안·인식 요법 등이 이용됩니다.

세계의 외상후 스트레스 장애(PTSD : Post-Traumatic Stress Disorder) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발 및 출시의 최신 동향, 임상시험 각 단계의 제품 목록, 주요 기업 개요, 주요 치료제 개요, 최신 업계 동향 등의 정보를 전해드립니다.

목차

서론

  • 분석 범위

외상후 스트레스 장애(PTSD) 개요

치료제 개발

  • 외상후 스트레스 장애(PTSD)용 파이프라인 제품 : 개요
  • 외상후 스트레스 장애(PTSD)용 파이프라인 제품 : 비교 분석

외상후 스트레스 장애(PTSD) : 각 기업에서 개발중인 치료제

외상후 스트레스 장애(PTSD) : 대학/연구기관에서 연구중인 치료제

외상후 스트레스 장애(PTSD) : 파이프라인 제품 개요

  • 후기 단계 제품
  • 임상 단계 제품
  • 초기 단계 제품
  • 미확인 단계 제품

외상후 스트레스 장애(PTSD) : 개발중인 제품 목록(기업별)

외상후 스트레스 장애(PTSD) : 연구중인 제품 목록(대학/연구기관별)

외상후 스트레스 장애(PTSD) 치료제 개발에 참여하고 있는 기업

  • Addex Therapeutics Ltd
  • Amorsa Therapeutics Inc.
  • Azevan Pharmaceuticals, Inc.
  • Catalyst Pharmaceutical Partners, Inc.
  • Eli Lilly and Company
  • HolsboerMaschmeyer NeuroChemie GmbH
  • Humanetics Corporation
  • Intra-Cellular Therapies, Inc.
  • INVENT Pharmaceuticals, Inc.
  • Marinus Pharmaceuticals, Inc.
  • Neuralstem, Inc.
  • NeuroNascent, Inc.
  • Omeros Corporation
  • Otsuka Holdings Co., Ltd.
  • Polleo Pharma Limited
  • Synchroneuron Inc.
  • Tonix Pharmaceuticals Holding Corp.
  • Turing Pharmaceuticals AG
  • Vanda Pharmaceuticals Inc.

외상후 스트레스 장애(PTSD) : 치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 표적별
  • 작용기서별
  • 투여 방법별
  • 분자 종류별

치료제 개요

  • acamprosate calcium SR
    • 제품 개요
    • 기능 메커니즘
    • 연구개발(R&D) 진전 상황
  • ADX-71743
  • AM-3506
  • brexpiprazole
  • CPP-115
  • Drug for Post-Traumatic Stress Disorders
  • Drugs to Inhibit FAAH for CNS Disorders
  • Drugs to Modulate NPSR for Anxiety Disorder
  • ganaxolone
  • HL-9001
  • IC-87201
  • iloperidone
  • INV-170
  • ITI-007
  • ketamine hydrochloride
  • NNI-351
  • NSI-189
  • Rycal
  • S-107
  • Small Molecule to Target GPR151 for CNS Diseases
  • Small Molecule to Target GPR83 for CNS and Immunological Disorders
  • Small Molecules for Post-Traumatic Stress Disorder
  • Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders
  • Small Molecules to Antagonize mGluR7 For Central Nervous System Disorders
  • Small Molecules to Antagonize mGluR7 for Post-Traumatic Stress Disorders and Acute Stress Disorder
  • Small Molecules to Antagonize TLR-4 for CNS Disorders
  • SRX-246
  • TNX-102
  • Vaccine for CNS Disorders
  • vigabatrin
  • ZL-006

외상후 스트레스 장애(PTSD) : 파이프라인 제품의 최신 동향

외상후 스트레스 장애(PTSD) : 개발이 휴지 상태인 제품

외상후 스트레스 장애(PTSD) : 개발이 중지된 제품

외상후 스트레스 장애(PTSD) 관련 제품 개발 마일스톤

  • 주목해야 할 최신 동향과 프레스 릴리스

부록

도표

KSM 16.04.11

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019 (Contd..1), H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Actinogen Medical Ltd, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Addex Therapeutics Ltd, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Amorsa Therapeutics Inc, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Anagin Inc, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Aptinyx Inc, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Armgo Pharma Inc, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Artelo Biosciences Inc, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Azevan Pharmaceuticals Inc, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Catalyst Pharmaceuticals Inc, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Chronos Therapeutics Ltd, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Corcept Therapeutics Inc, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Eli Lilly and Co, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Embera NeuroTherapeutics Inc, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Immodulon Therapeutics Ltd, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Johnson & Johnson, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Lixte Biotechnology Holdings Inc, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by NeuroNascent Inc, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Omeros Corp, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Otsuka Holdings Co Ltd, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Sanofi, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by SpringWorks Therapeutics LLC, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, H1 2019 (Contd..1), H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Discontinued Products, H1 2019

List of Figures

  • Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Top 10 Targets, H1 2019
  • Number of Products by Stage and Top 10 Targets, H1 2019
  • Number of Products by Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Molecule Types, H1 2019
  • Number of Products by Stage and Molecule Types, H1 2019

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2019, provides an overview of the Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline landscape.

Post-traumatic stress disorder (PTSD) is a mental health condition that's triggered by a terrifying event either experiencing it or witnessing it. Symptoms include flashbacks, nightmares and severe anxiety, as well as uncontrollable thoughts about the event. Treatment includes antidepressants, anti-anxiety and cognitive therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Post-Traumatic Stress Disorder (PTSD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 4, 19, 6 and 2 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 3 and 1 molecules, respectively.

Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD) (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Post-Traumatic Stress Disorder (PTSD) - Overview
  • Post-Traumatic Stress Disorder (PTSD) - Therapeutics Development
  • Post-Traumatic Stress Disorder (PTSD) - Therapeutics Assessment
  • Post-Traumatic Stress Disorder (PTSD) - Companies Involved in Therapeutics Development
  • Post-Traumatic Stress Disorder (PTSD) - Drug Profiles
  • Post-Traumatic Stress Disorder (PTSD) - Dormant Projects
  • Post-Traumatic Stress Disorder (PTSD) - Discontinued Products
  • Post-Traumatic Stress Disorder (PTSD) - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q